SCHEMBL30955414

SCHEMBL30955414

CC(C)(C)OC(=O)Nc1ccnc(CCl)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.49
▸ SREBF2 Q12772 1/20 0.47
▸ CYP17A1 P05093 4/20 0.46
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ MAPKAPK2 P49137 2/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ RPS6KB1 P23443 1/20 0.41
▸ PRKCI P41743 1/20 0.40
▸ SMARCA2 P51531 1/20 0.40
▸ SMARCA4 P51532 1/20 0.40
▸ ANO1 Q5XXA6 1/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23168284 0.87 SREBF2 (0.47) ATRSREBF2CYP17A1CA12CA1
SCHEMBL30530884 0.84 SREBF2 (0.45) ATRSREBF2CYP17A1CA12CA1
SCHEMBL30955481 0.83 SREBF2 (0.44) ATRSREBF2CYP17A1CA12CA1
SCHEMBL6591045 0.83 SREBF2 (0.49) ATRSREBF2CYP17A1CA12CA1
SCHEMBL28152360 0.83 SREBF2 (0.44) ATRSREBF2CYP17A1CA12CA1
SCHEMBL1501665 0.82 SMARCA2 (0.57) ATRCYP17A1CA12CA1CA9
SCHEMBL30955460 0.82 SREBF2 (0.46) ATRSREBF2CYP17A1CA12CA1
SCHEMBL28268052 0.82 SREBF2 (0.44) ATRSREBF2CYP17A1CA12CA1
SCHEMBL30955394 0.81 SREBF2 (0.43) ATRSREBF2CYP17A1CA12CA1
SCHEMBL30955401 0.81 SREBF2 (0.48) ATRSREBF2CYP17A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024131938-A1 QUINAZOLINE COMPOUND AND USE THEREOF 赛诺哈勃药业(成都)有限公司 2024-06-27 — — WO disclosed
Send feedback